The decision tree shows the associated probabilities, QALYs and costs for each clinical outcome arising from either the LVOS arm or the SSIR arm. An ICUR of $644/QALY favoring LVOS was calculated based off of its clinical-effectiveness gain of 7.11 QALY at an additional cost of $4,579.43 (partly due to the additional costs of radiation treatment and the bilateral operation needed for LVOS compared to no radiation and unilateral surgery for SSIR). This proved that LVOS is a cost-effective surgical option given that a surgical approach is deemed cost-effective if its ICUR is less than $50,000/QALY. One-way sensitivity analyses underscored the degree by which LVOS was costeffective. For example, LVOS became cost-ineffective when a successful LVOS cost more than $50,000. Similarly, probabilistic sensitivity analysis using Monte-Carlo simulation showed that even with varying multiple variables at once, results tended to favor our conclusion supporting the costeffectiveness of LVOS.
RESULTS:
The decision tree shows the associated probabilities, QALYs and costs for each clinical outcome arising from either the LVOS arm or the SSIR arm. An ICUR of $644/QALY favoring LVOS was calculated based off of its clinical-effectiveness gain of 7.11 QALY at an additional cost of $4,579.43 (partly due to the additional costs of radiation treatment and the bilateral operation needed for LVOS compared to no radiation and unilateral surgery for SSIR). This proved that LVOS is a cost-effective surgical option given that a surgical approach is deemed cost-effective if its ICUR is less than $50,000/QALY. One-way sensitivity analyses underscored the degree by which LVOS was costeffective. For example, LVOS became cost-ineffective when a successful LVOS cost more than $50,000. Similarly, probabilistic sensitivity analysis using Monte-Carlo simulation showed that even with varying multiple variables at once, results tended to favor our conclusion supporting the costeffectiveness of LVOS.
CONCLUSION:
For the appropriate patients with moderate to large sized breasts with breast cancer, large volume displacement oncoplastic surgery is cost-effective in breast cancer treatment compared to mastectomy with single staged implant reconstruction. This provides yet another reasonable breast conservation surgical option for the breast cancer patient. Johns Hopkins, Baltimore, MD PURPOSE: Enhanced Recovery After Surgery pathway (ERAS) was introduced in 1997 as a multimodal approach to improve postoperative outcomes. ERAS pathways have become increasingly accepted and implemented for many procedures in several surgical specialties, which successfully improved postoperative pain control, reduced length of stay (LOS), and reduced costs. However, there is yet no widely accepted ERAS for microsurgical breast reconstruction. The purpose of this study is to conduct a systematic review of the current literature on ERAS for microsurgical breast reconstruction and to do a meta-analysis to determine whether the use of ERAS in microsurgical breast reconstruction cases is associated with any changes in LOS, or postoperative morbidity.
METHODS:
We searched PubMed, Embase, Cochrane, Scopus and Web of Science for all randomized control trials, case-control, retrospective cohort, and prospective cohort studies published prior to June 2016 that contain original data investigating ERAS in microsurgical breast reconstruction in relation to postoperative LOS and morbidity. Studies found were screened using eligibility criteria previously agreed upon by the authors. Meta-analysis, odds ratio(OR) and 95% confidence interval (CI) were used to pool acquired data.
RESULTS:
The initial search identified 87 studies. Two independent screeners identified four original articles, with a pooled population of 676 patients that met the inclusion criteria. Of those, there were three retrospective studies and one prospective study. While LOS data was not homogenous enough to do a meta-analysis, ERAS LOS was reported in three studies to be lower when compared to the previous protocols, from 6.6 to 3.9 days (p < 0.001), 7.4 to 6.2 days (p< 0.001), and 6.2 to 3.1 days (p< 0.001). Two studies were pooled for the meta-analysis of postoperative morbidity, which suggested that ERAS was not associated with changes in 30 days postoperative morbidity; partial flap loss p=0.44 (OR 1.80, 95% CI: 0.41-7.95), total flap loss p=0.91 (OR 1.07, 95% CI: 0.35-3.23), breast hematoma p=0.69 (OR 1.15, 95% CI: 0.59-2.21), donor site infection p=0.53 (OR 1.29, 95% CI: 0.58-2.86), urinary tract infection p=0 .29 (OR 0.37, 95% CI: 0.06-2.29), and pneumonia p=0.42 (OR 1.81, 95% CI: 0.43-7.66).
CONCLUSION:
Our review suggests that ERAS in microsurgical breast reconstruction is associated with lower LOS. Meta-analysis suggests that ERAS is not associated with increased postoperative morbidity. The results of this review are limited by the low number of prospective and randomized controlled trials, the small number of patients and studies included, and the moderate heterogeneity of the groups evaluated within the included studies. PURPOSE: Management of chest wall reconstruction (CWR) following oncologic resection is challenging due to the nature if pathology, the radical procedure, and the employment of prosthetic materials required for biomechanical stability. Traditional material for CWR includes synthetic prosthesis (i.e. polypropylene or polytetrafluorethylene). However, biologic meshes might result in less wound complications. The aim of this study was to determine whether acellular dermal matrix (ADM) is associated with a lower incidence of complications following chest wall reconstruction for an oncologic resection defect compared to synthetic mesh.
METHODS:
We performed a retrospective study of consecutive patients who underwent complex chest wall reconstruction (CWR) using synthetic mesh (SM) or ADM at a single center. Only defects involving at least one rib resection and reconstructed with both mesh and flaps were included. We therefore excluded flap only or mesh only reconstructions and patients with a follow-up <6 months. Patients' characteristics, treatment factors and outcomes were prospectively documented. The primary outcome measure for the SM versus ADM groups was surgical site occurrence (SSO). Secondary outcomes were specific wound healing, infective, and medical complications, as well as 90-day mortality and re-operation.
RESULTS:
One hundred forty six patients (95 [65.1%] with SM; 51 [34.9%] with ADM) underwent CWR with both mesh and flaps for repair of oncologic resection defect. Mean follow-up was 29.3 months (range, 6-109), mean age was 51.5 years, and mean defect area was 173.8 cm 2 . SM CWR patients underwent more rib resections (2.7 vs 2.0 ribs, P = 0.006) but similar sternal resections (29.5% vs 23.5%; P = 0.591) than ADM CWR patients. SM CWR patients experienced a significantly higher SSO (32.6% vs 15.7%, P = 0.027) than ADM CWR patients. The 2 groups had similar rates of specific wound healing complications. No differences in 90-day mortality, nor re-operations were observed. Multivariable analysis identified prolonged hospital stay, comorbidity, prolonged operative time, and synthetic repairs to be predictive factors of SSO.
CONCLUSION: ADM CWR results in less SSO than SM CWR, when combined with soft tissue flap coverage. Surgeons should consider selectively employing ADM for CWR in patients at higher wound healing risk of complications.
